December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled

In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals Professor and Deputy Director, Neuromedicines Discovery Centre at Monash University and CEO of Phrenix Therapeutics Atypical chemokine receptors: emerging therapeutic targets in cancer. Reports Q3 2022 Financial Results and Provides Corporate Update Peter Suzdak, Ph.D. joins Function Therapeutics NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist Confo Therapeutics

Pina Cardarelli from GPCR Therapeutics as well as Dr. Marta Filizola. Molecular Mechanisms and Therapeutic Prospects Luminal Chemosensory Cells in the Small Intestine Melanopsin OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor OMass Therapeutics's Foundation and the 2022 Benjamin Franklin Medal in Chemistry from The Franklin Institute VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron 3.